Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

318.46
Delayed Data
As of Sep 22
 +3.43 / +1.09%
Today’s Change
244.28
Today|||52-Week Range
330.00
+21.92%
Year-to-Date
AbbVie's Venclexta Achieves Primary Endpoint
Sep 19 / GuruFocus News - Paid Partner Content
Biosimilar 2017 Progress Report: Stocks in Focus
Sep 14 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close315.03
Today’s open311.30
Day’s range311.30 - 319.34
Volume988,098
Average volume (3 months)1,401,676
Market cap$67.3B
Dividend yield--
Data as of 3:59pm ET, 09/22/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+5.98%
Earnings growth (next 5 years)+5.71%
Revenue growth (last year)+9.37%
P/E ratio20.9
Price/Sales6.09
Price/Book5.66

Competitors

 Today’s
change
Today’s
% change
ILMNIllumina Inc+1.17+0.58%
GILDGilead Sciences+0.65+0.79%
KITEKite Pharma Inc-0.08-0.04%
BIVVBioverativ Inc+0.60+1.07%
Data as of 4:00pm ET, 09/22/2017

Financials

Next reporting dateOctober 25, 2017
EPS forecast (this quarter)$5.65
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Senior Vice President-
US Therapeutic Operations
Alisha A. Alaimo
Corporate headquarters
Cambridge, Massachusetts

Forecasts